Tag Archives: brli

Illumina Falls On HiSeq Rival; Bio-Reference Up on Q2

Genomics firm Illumina (ILMN) dipped Monday on news of a competing high-end gene sequencer, while lower-end rival Bio-Reference Laboratories (BRLI) rose despite missing quarterly expectations. At the European Human Genetics Conference over the weekend, Complete Genomics, a unit of BGI (formerly Beijing Genomics Institute), previewed its Revolocity sequencing system, a “supersequencer” designed to deliver as many as 30,000 whole genome sequences

Opko Health Swallowing Bigger Fish Bio-Reference Labs

Opko Health (OPK) agreed to buy lab services company Bio-Reference Laboratories (BRLI) for $1.47 billion in stock Thursday. Bio-Reference shareholders will get 2.75 shares of Opko stock for each share held. Based on Opko’s closing price of 19.12 Wednesday, the 2.75-for-1 deal valued Bio-Reference at 52.58 a share. Opko stock hit a record high of 19.20 Wednesday. Opko stock, however, was near 17.75, down 7% in morning trading on the stock market

Bio-Reference Labs Slashes Guidance; Stock Plunges

Diagnostic testing company Bio-Reference Laboratories (BRLI) on Wednesday slashed its profit guidance for the quarter and year, sending shares crashing 20% in morning trading on the stock market today. Bio-Reference stock had risen nearly 35% from Oct. 8 through Tuesday. The company says it expects to report revenue for its fiscal Q4 ended Oct. 31 of about $192 million, which actually is higher than analysts’ consensus of $189 million, according